Trial
NCT05216510
Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Tonix Pharmaceuticals, Inc.
Collaborators
Premier Research
Condition
Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2
Intervention
TNX-2110
Why stopped
Lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-11-06